{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:14:46Z","timestamp":1792786486591,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":958,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["KFO 196"],"award-info":[{"award-number":["KFO 196"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Wissenschaftsministerium des Saarlandes"},{"name":"Bayer A6"},{"name":"Boehringer"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medtronic"},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Boehringer"},{"name":"Pfizer\/Bristol-Myers Squibb","id":[{"id":"https:\/\/ror.org\/00gtmwv55","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Astellas"},{"name":"Merck"},{"name":"Portola"},{"name":"Biotronic"},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AstraZeneca"},{"name":"AstraZeneca"},{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.jacc.2010.09.017","type":"journal-article","created":{"date-parts":[[2010,12,8]],"date-time":"2010-12-08T04:27:01Z","timestamp":1291782421000},"page":"2067-2076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation"],"prefix":"10.1016","volume":"56","author":[{"given":"Stephan H.","family":"Schirmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Baumh\u00e4kel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ruprecht","family":"Neuberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H.","family":"Hohnloser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle C.","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2010.09.017_bib1","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2010.09.017_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinte.1995.00430050045005","article-title":"Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications","volume":"155","author":"Feinberg","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2010.09.017_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","article-title":"Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence","volume":"114","author":"Miyasaka","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.09.017_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00392-006-0344-4","article-title":"Atrial fibrillation\u2014patients at high risk for cerebral embolism","volume":"95","author":"Bernhardt","year":"2006","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacc.2010.09.017_bib5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0140-6736(87)90174-7","article-title":"Risk of stroke in non-rheumatic atrial fibrillation","volume":"1","author":"Flegel","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.017_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1160\/TH07-08-0508","article-title":"Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data","volume":"99","author":"Hughes","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.09.017_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1160\/TH08-05-0331","article-title":"Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis","volume":"100","author":"Lip","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.09.017_bib8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.STR.0000166053.83476.4a","article-title":"Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study","volume":"36","author":"Marini","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2010.09.017_bib9","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke severity in atrial fibrillation: the Framingham study","volume":"27","author":"Lin","year":"1996","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2010.09.017_bib10","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/eurheartj\/ehp124","article-title":"Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients","volume":"30","author":"B\u00f6hm","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2010.09.017_bib11","first-page":"e21","article-title":"Heart disease and stroke statistics\u20142009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"119","author":"Lloyd-Jones","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.09.017_bib12","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2010.09.017_bib13","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2010.09.017_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2010.09.017_bib15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation","volume":"349","author":"Hylek","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.09.017_bib16","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"Connolly","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.09.017_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0002-9343(02)01131-2","article-title":"Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial","volume":"113","author":"Matchar","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2010.09.017_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.017_bib19","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.017_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.molmed.2008.08.001","article-title":"Factor Xa: at the crossroads between coagulation and signaling in physiology and disease","volume":"14","author":"Borensztajn","year":"2008","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jacc.2010.09.017_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0735-1097(02)02868-1","article-title":"Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects","volume":"41","author":"Sarich","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.09.017_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.CIR.97.3.251","article-title":"Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor","volume":"97","author":"Xiao","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.09.017_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1160\/TH07-03-0183","article-title":"In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate","volume":"98","author":"Wienen","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.09.017_bib24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2010.09.017_bib25","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1056\/NEJMoa035162","article-title":"Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement","volume":"349","author":"Francis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.09.017_bib26","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.017_bib27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2010.09.017_bib28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.017_bib29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jacc.2010.09.017_bib30","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.09.017_bib31","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.jacc.2010.09.017_bib32","first-page":"95","article-title":"Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomized trial (abstr)","author":"Huo","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jacc.2010.09.017_bib33","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.09.017_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Ginsberg","year":"2009","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.jacc.2010.09.017_bib35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.thromres.2010.03.021","article-title":"Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials","volume":"126","author":"Friedman","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2010.09.017_bib36","article-title":"Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement","volume":"4","author":"Salazar","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2010.09.017_bib37","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.09.017_bib38","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.09.017_bib39","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.09.017_bib40","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00392-009-0085-2","article-title":"Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more","volume":"98","author":"Schirmer","year":"2009","journal-title":"Clin Res Cardiol"},{"issue":"Suppl A","key":"10.1016\/j.jacc.2010.09.017_bib41","first-page":"A1","article-title":"Dabigatran versus warfarin in atrial fibrillation in patients with low, moderate and high CHADS2 score: a RE-LY subgroupd analysis (abstr)","volume":"55","author":"Oldgren","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.09.017_bib42","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"Suppl A","key":"10.1016\/j.jacc.2010.09.017_bib43","first-page":"A4","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion (abstr)","volume":"55","author":"Koti","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.09.017_bib44","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/eurheartj\/ehq117","volume":"31","author":"Lip","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2010.09.017_bib45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00392-010-0154-6","article-title":"Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more","volume":"99","author":"Jacobshagen","year":"2010","journal-title":"Clin Res Cardiol"},{"issue":"Suppl A","key":"10.1016\/j.jacc.2010.09.017_bib46","first-page":"A4","article-title":"Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RE-LY study (abstr)","volume":"55","author":"Healey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.09.017_bib47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1160\/TH09-08-0579","article-title":"Economic evaluation of dabigatran etexilate for the preventionof venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement","volume":"103","author":"Wolowacz","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.09.017_bib48","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehp318","article-title":"Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists","volume":"30","author":"Lip","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2010.09.017_bib49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1160\/TH09-07-0509","article-title":"Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation","volume":"103","author":"Olsson","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.09.017_bib50","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1538-7836.2007.02429.x","article-title":"In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban","volume":"5","author":"Gerotziafas","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.09.017_bib51","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(09)61454-9","article-title":"Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial","volume":"374","author":"Sabatine","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.017_bib52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2141.2008.07300.x","article-title":"Rivaroxaban\u2014an oral, direct Factor Xa inhibitor\u2014has potential for the management of patients with heparin-induced thrombocytopenia","volume":"143","author":"Walenga","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacc.2010.09.017_bib53","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0091270006292127","article-title":"Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban\u2014an oral, direct factor Xa inhibitor\u2014are not affected by aspirin","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2010.09.017_bib54","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.09.017_bib55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.017_bib56","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.09.017_bib57","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.017_bib58","first-page":"114","article-title":"Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism: the Einstein-Extension study (abstr)","author":"Buller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2010.09.017_bib59","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study","volume":"159","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.09.017_bib60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1538-7836.2008.02848.x","article-title":"Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants","volume":"6","author":"B\u00fcller","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.09.017_bib61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.017_bib62","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.09.017_bib63","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.09.017_bib64","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.09.017_bib65","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.09.017_bib66","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ahj.2009.08.026","article-title":"Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment","volume":"159","author":"Eikelboom","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.09.017_bib68","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)","volume":"101","author":"Turpie","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.09.017_bib69","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, rolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2010.09.017_bib70","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1538-7836.2010.03748.x","article-title":"Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty","volume":"8","author":"Eriksson","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.09.017_bib71","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1538-7836.2007.02436.x","article-title":"A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement","volume":"5","author":"Agnelli","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.09.017_bib72","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2010.09.017_bib73","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/hh1901.097084","article-title":"Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting wnzyme-1 wxpression by sistinct pathways: role of Rho\/ROCK and mitogen-activated protein kinase","volume":"89","author":"Eto","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2010.09.017_bib74","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1161\/01.CIR.0000142867.26182.32","article-title":"Thrombin stimulates human endothelial arginase enzymatic activity via RhoA\/ROCK pathway: implications for atherosclerotic endothelial dysfunction","volume":"110","author":"Ming","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.09.017_bib75","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1084\/jem.20071427","article-title":"Protease-activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo","volume":"205","author":"Chen","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.jacc.2010.09.017_bib76","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.0000038140.80105.AD","article-title":"Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice","volume":"106","author":"Inoue","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.09.017_bib77","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.09.017_bib78","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.109.849539","article-title":"Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-C{beta}-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability","volume":"120","author":"Seehaus","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.09.017_bib79","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.2353\/ajpath.2010.090406","article-title":"Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease","volume":"176","author":"Yin","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacc.2010.09.017_bib80","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1161\/CIRCRESAHA.109.199984","article-title":"Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, RhoA, and myocardin","volume":"105","author":"Martin","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2010.09.017_bib81","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1002\/art.24935","article-title":"Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts","volume":"60","author":"Bogatkevich","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jacc.2010.09.017_bib82","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1182\/blood-2007-10-120295","article-title":"Regenerative repair after endoluminal injury in mice with specific antagonism of protease activated receptors on CD34+ vascular progenitors","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2010.09.017_bib83","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1160\/TH09-09-0627","article-title":"Thrombin receptors in vascular smooth muscle cells\u2014function and regulation by vasodilatory prostaglandins","volume":"103","author":"Schror","year":"2010","journal-title":"Thromb Haemost"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109710041860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109710041860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:42:00Z","timestamp":1760013720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109710041860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":82,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0735109710041860"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2010.09.017","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2010.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}